CoVac-1 vaccine shows promise for immunocompromised patients

May 2, 2022

At the recent American Association for Cancer Research (AACR) meeting in New Orleans, spoke with the University of Tübingen’s Dr. Juliane Walz, professor of peptide-based immunotherapies, and research associate Claudia Tandler about the promising results their CoVac-1 vaccine has shown in immunocompromised patients.

Walz's team used their expertise with cancer therapeutics to develop a vaccine that induces T cells in immunocompromised patients who do not produce an adequate immune response to other vaccines.

The unit's research has shown that the vaccine induced generation of T cells in healthy volunteers much more effectively than either previous COVID infection or other vaccines. The effect was long lasting and was not diminished with any of the known COVID-19 variants, such as omicron.

A trial with a cohort of immunocompromised patients showed effective T-cell response in 86% of the patients and distinctly higher T-cell response than with current approved vaccines. The team is now looking forward to phase III approval trials and deciding how the vaccine will be further developed.

Context Therapeutics highlights data on ONA-XR and CLDN6 at AACR 2022
Context Therapeutics released preclinical data from two of its clinical programs to treat women’s cancers at the American Association for Cancer Research...
AACR 2022 video: Project GENIE spurs sharing of real-world data
At this week's American Association for Cancer Research (AACR) 2022 annual meeting, spoke with Shawn Sweeney, PhD, the director...
AACR 2022 video: AACR taskforce tackles public trust in science
NEW ORLEANS -- On day four of the American Association for Cancer Research (AACR) meeting, spoke with Dr. Jesse Nodora, PhD,...
Video from AACR 2022: Does the microbiome predict precervical cancer risk?
NEW ORLEANS - Does the microbiome provide clues to the precervical cancer risk of women? This is the question that Katherine Tossas, PhD, is investigating....
Video from AACR 2022: Next-gen pathology tools for cancer research
NEW ORLEANS - What do the next-generation of pathology tools for cancer research look like, and how can pathologists contribute to those technologies...

Copyright © 2022

Last Updated 7/20/2022 2:06:38 PM